Does Risperdal Cause Gynecomastia in Males?
Yes, Risperdal (risperidone) causes gynecomastia—enlarged breast tissue—in some males. This side effect stems from the drug's elevation of prolactin levels, a hormone that stimulates breast tissue growth. Clinical data and lawsuits confirm this link, with incidence rates up to 10% in pediatric patients and higher in adults on long-term use.[1][2]
How Common Is Gynecomastia with Risperdal?
Studies show gynecomastia occurs in 0.5-1.5% of adult males on risperidone, but rates climb to 5-10% in boys and adolescents, especially at higher doses (over 2 mg/day). A 2010 meta-analysis of antipsychotics found risperidone had the highest prolactin elevation among atypicals, correlating directly with gynecomastia cases.[3] Post-marketing reports to the FDA exceed 1,000 for males, many requiring surgery.[1]
Why Does Risperdal Raise Prolactin Leading to Gynecomastia?
Risperidone blocks dopamine D2 receptors more potently than other atypicals, reducing dopamine's inhibition of prolactin release from the pituitary. Elevated serum prolactin (hyperprolactinemia) persists in 50-90% of users, triggering mammary gland development. This effect reverses in most cases after stopping the drug, but permanent tissue growth can occur with prolonged exposure.[2][4]
What Do Patients and Lawsuits Report?
Thousands of lawsuits against Janssen (Risperdal's maker) allege failure to warn about gynecomastia risks, particularly in boys treated for autism or ADHD. Settlements total over $2.5 billion since 2013, with cases documenting boys developing breasts as large as D-cups. Plaintiffs often cite inadequate labeling until 2006 FDA updates.[1][5]
How Does Risperdal Compare to Other Antipsychotics?
Risperidone induces gynecomastia more than low-prolactin drugs like aripiprazole (Abilify, near-zero risk) or quetiapine (Seroquel, minimal). Paliperidone (Invega), risperidone's metabolite, carries similar risks. Switching to prolactin-sparing alternatives often resolves symptoms.[3][4]
Can Gynecomastia from Risperdal Be Reversed?
It often reverses within months of dose reduction or discontinuation, but surgical removal (mastectomy) is common for persistent cases, especially in adolescents. Monitoring prolactin levels and breast exams is standard for at-risk patients.[2]
What Warnings Are on the Label?
Risperdal's label lists gynecomastia under hyperprolactinemia warnings, noting potential for galactorrhea, amenorrhea, and breast enlargement. The FDA requires prolactin monitoring in children and advises against use if levels exceed normal ranges.[1]
Sources
[1]: FDA Risperdal Label
[2]: PubMed: Risperidone-induced gynecomastia review
[3]: JAMA Psychiatry meta-analysis on antipsychotics and prolactin
[4]: American Journal of Psychiatry: Hyperprolactinemia mechanisms
[5]: Reuters: Risperdal lawsuit settlements